The stock in focus - Neumora Therapeutics Inc. (NMRA) is a clinical-stage biopharmaceutical company that engages in developing treatments for brain, neuropsychiatric, and neurodegenerative diseases in the U.S.
Its lead candidate, Navacaprant (NMRA-140), is a once-daily oral kappa opioid receptor antagonist currently in Phase 3 trials for major depressive disorder. The company is also advancing NMRA-511, now in Phase 1 trials for agitation associated with dementia due to Alzheimer's disease.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com